$100M for Tmunity’s cancer gene therapy from China, US investors – Philly.com (blog)
Philly.com (blog) |
$100M for Tmunity’s cancer gene therapy from China, US investors
Philly.com (blog) The investors are led by Ping An Ventures, an arm of China’s largest insurer, which has been plowing profits into biotech; Gilead Sciences, the California-based biopharma company, which in August said it would pay $12 billion for cell therapy developer … Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean ParkerForbes Tmunity Reels in $100M for “Next Generation” Cancer ImmunotherapyXconomy Tmunity Therapeutics Raises $100 Million in Series A Financing to Advance Portfolio of Next-Generation T cell …Digital Journal San Francisco Business Times –Philadelphia Business Journal all 10 news articles » |
Forbes |
Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean Parker
Forbes Both attempt to use genetically modified T–cells, which have proven effective in late-stage blood cancers, against more common solid tumors, which are more difficult for the immune system to penetrate. One treatment is what is known as a chimeric … Tmunity Reels in $100M for “Next Generation” Cancer ImmunotherapyXconomy |
|
BioLineRx’s immunotherapy candidate AGI-134 shows positive effect in preclinical melanoma studies; shares ahead 8 …
Seeking Alpha BioLineRx (NASDAQ:BLRX) is up 8% premarket on light volume in response to its announcement of positive results from preclinical studies assessing immunotherapy candidate AGI-134. The data will be presented at the ASCO-SITC Clinical Immuno-Oncology … BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical …PR Newswire (press release) |
Labiotech.eu (blog) |
uniQure Gets Orphan Medicinal Product Designation for Huntington’s Gene Therapy
Labiotech.eu (blog) The EMA has given uniQure’s gene therapy candidate for Huntington’s disease Orphan Medicinal Product Designation, which the company hopes to move into the clinic this year. uniQure is known for Glybera, Europe’s first gene therapy. The company’s … |